NAD+ Booster NMNH Proved for Safety and Efficacy

Overview


NAD-Booster-NMNH-Proved-for-Safety-and-Efficacy.jpg

NMNH, short for Reduced Beta-Nicotinamide Mononucleotide, refers to the reduced form of NMN. Preclinical studies show that NMNH demonstrates a remarkable 10X surge in NAD+ levels.

EffePharm's UthPeak™ NMNH has completed toxicology and efficacy tests, affirming its safety and health potential in the dietary supplement market. Our animal tests highlight its anti-aging, anti-fatigue, and cardiovascular health benefits. Clinical trials on humans are currently underway. Partnering with Double Wood, the first UthPeak™ NMNH product has launched on Amazon. Download the flyer below to learn more.

This content is paid by Effepharm Ltd, and any views and opinions expressed do not necessarily reflect those of NutraIngredients.com

Download Now


Latest Content

Related Resources

The Global Regulatory Advantage Behind UTHEVER® NMN

The Global Regulatory Advantage Behind UTHEVER® NMN

Paid for by Effepharm Ltd

White Paper

Regulatory uncertainty remains one of the biggest challenges for NMN brands. Choosing the wrong ingredient could lead to compliance risks & market restrictions.

Discover UTHEVER® NMN’s Global Regulatory Landscape

Discover UTHEVER® NMN’s Global Regulatory Landscape

Paid for by Effepharm Ltd

White Paper

NMN has long faced regulatory challenges. Today, that landscape is changing. We consistently invest in scientific research & quality development, aiming to establish UTHEVER® as the world’s most compliant NMN ingredient brand.

Supplier Info Centre

Effepharm-Ltd.jpg

For more product information visit Effepharm Ltd.